📰 **Novartis' Pluvicto Shows Lower Risk Of PSA Progression In Phase 3 PSMAddition Trial For MHSPC **

(RTTNews) - Novartis (NVS) announced new data from the Phase III PSMAddition trial demonstrating improved prostate-specific antigen (PSA) responses with Pluvicto combined with standard of care (SoC) in PSMA-positive metastatic hormone-sensitive prostate cancer (mHSPC).

🔗 https://www.nasdaq.com/articles/novartis-pluvicto-shows-lower-risk-psa-progression-phase-3-psmaddition-trial-mhspc

#markets #news